Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
MWN-AI** Summary
Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company, is set to present a poster at the 2025 Military Health System Research Symposium (MHSRS) held from August 4-7 in Orlando, Florida. The presentation, titled "Quantitative Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate," will be moderated by CEO Stephan Jackman and aims to highlight innovative approaches in military suicide prevention.
The study investigates how AL001, a novel lithium-delivery system, compares to traditional lithium carbonate in terms of brain-to-plasma lithium exposure in subjects with post-traumatic stress disorder (PTSD). The motivation behind this research is to better characterize the profile of AL001, which is designed to mitigate toxicities typically associated with lithium treatments while targeting effective lithium delivery to the brain. By comparing brain lithium concentrations between the two formulations, Alzamend aims to establish a database that considers various neuropsychiatric conditions.
Jackman expressed optimism about the opportunity to engage with Department of Defense funding directors at the symposium, with hopes to secure non-dilutive funding through grants to support the advancement of their technology without compromising shareholder value.
Alzamend's current pipeline includes AL001, which combines lithium with salicylate and L-proline to improve safety and efficacy in treating Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD. The company is advancing its research with a Phase II trial initiated in May 2025 and anticipates presenting topline data by year-end.
Overall, Alzamend Neuro is focused on innovation in mental health therapies, aiming for effective treatments while enhancing safety profiles, making a significant contribution to military and veteran health outcomes.
MWN-AI** Analysis
Alzamend Neuro, Inc. (Nasdaq: ALZN) is preparing for a significant engagement at the 2025 Military Health System Research Symposium, presenting their study on AL001, a novel lithium-delivery system for conditions like PTSD and Alzheimer's disease. This platform presents a unique opportunity for investors to reassess Alzamend’s potential in the biopharmaceutical sector, especially given their focus on addressing military and veteran mental health—a crucial area for government support and funding.
The study aims to explore differences in lithium brain-to-plasma exposure between AL001 and traditional lithium carbonate, a measurement critical for optimizing treatment protocols for PTSD. As the military grapples with rising suicide rates among service members, the demand for innovative, effective therapies is higher than ever. This points to a potentially lucrative market for Alzamend, especially if they can secure non-dilutive funding through grants or partnerships with the Department of Defense.
Investors should note that Alzamend has successfully initiated Phase II clinical studies and expects to release topline data by the end of 2025, a crucial milestone that could significantly impact stock performance. With promising preclinical findings indicating better brain absorption and reduced systemic toxicity compared to traditional lithium options, Alzamend may position itself as a leader in the development of safer, more effective treatments.
While the biopharmaceutical sector carries inherent risks related to clinical results and market acceptance, the compelling nature of Alzamend’s innovations, coupled with its strategic positioning in an underserved market, presents a strong investment case. Potential upward momentum could be realized as the company continues its clinical trials and engages with stakeholders at the MHSRS event. Monitoring developments closely during and after this symposium will be essential for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs
- Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate
ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced it will have a poster presentation at the Military Health System Research Symposium (“ MHSRS ”), being held from August 4-7, 2025, in Orlando, Florida.
“Our upcoming poster presentation at MHSRS 2025 represents an exceptional opportunity to spotlight our cutting-edge innovation and its transformative potential for active-duty service members and military veterans,” said Stephan Jackman, Chief Executive Officer of Alzamend. “We are excited to engage with Department of Defense (DoD) funding directors to pursue non-dilutive funding through grants, which would further validate our technology and accelerate our advancement while strategically preserving shareholder value.”
Abstract MHSRS-25-14329 – Poster presentation:
Title : Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate
Session Title: Innovation and Current Directions in Military Suicide Prevention, Research, and Programs
Session Date and Time: Wednesday, August 6, 2025; 10:00AM ET – 12:00PM ET
Session Location: Gaylord Palms Resort & Convention Center, Kissimmee, FL
Presenter Details: Stephan Jackman, Chief Executive Officer, Alzamend Neuro, Inc.
Summary: The current study is designed to quantitate differences in lithium brain-to-plasma exposure in PTSD subjects between AL001 and lithium carbonate for the purpose of contributing to a composite database of analogously studied brain-plasma assessments that include data from healthy subjects and multiple additional neurodegenerative, neurological and neuropsychiatric disorders. Currently, AL001 is targeted for treatment of Alzheimer’s, BD type 1, MDD and PTSD. It’s anticipated that this study design may help target appropriate AL001 lithium systemic dosing for these indications in future studies. Using this study design, comparable target organ (brain) lithium concentrations may be quantitated between AL001 and lithium carbonate and, by equivalence inference, lithium citrate solution and syrup.
About AL001
AL001 is a novel lithium-delivery system that has the potential to provide the benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium. Results from Alzamend’s completed Phase IIA multiple-ascending dose study of AL001 in Alzheimer’s patients and healthy subjects identified a maximum tolerated dose (“ MTD ”), as assessed by an independent safety review committee. This MTD is designed to be unlikely to require therapeutic drug monitoring while providing lithium at a relatively modest but effective dose. AL001 is designed to favorably distribute lithium in the brain resulting in lower exposure of other body organs and an improved safety profile compared to currently marketed lithium salts. This can serve to mitigate or obviate the disadvantageously low ceiling for toxicity of marketed lithium salts that has limited their usefulness to patients and prescribers.
In collaboration with Massachusetts General Hospital as its clinical trial site, Alzamend initiated the first of five Phase II clinical studies of AL001 in May 2025, with the first study in healthy human subjects. Alzamend aims to explore the unique properties of AL001 and its potential to deliver lithium more effectively in the brain compared to marketed lithium salts. The study in healthy human subjects will serve as a baseline and assist Alzamend in determining the best path forward in Alzheimer’s, BD, MDD and PTSD patients by demonstrating AL001’s targeted effectiveness and reduced systemic side effects. Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments. Alzamend expects to present topline data from this study by the end of 2025.
About Alzamend Neuro
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at https://www.alzamend.com/ .
Contacts:
Email: Info@Alzamend.com or call: 1-844-722-6333
A PDF accompanying this announcement is available at:
http://ml.globenewswire.com/Resource/Download/d17e9294-accc-4f0f-857b-1c352c9a614f
A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/4ed3a543-69dc-4102-b467-2ce2711658be
FAQ**
How does Alzamend Neuro Inc. ALZN's innovative AL001 compare in lithium brain-to-plasma exposure to traditional lithium carbonate in PTSD subjects during the upcoming presentation at MHSRS 2025?
What specific strategies does Alzamend Neuro Inc. ALZN plan to employ to secure non-dilutive funding through grants from the Department of Defense following the MHSRS presentation?
In what ways could the findings from Alzamend Neuro Inc. ALZN's study on AL001 impact the future treatment landscape for military personnel suffering from PTSD?
How does Alzamend Neuro Inc. ALZN ensure the safety profile of AL001 in comparison to marketed lithium salts in terms of reducing systemic side effects and monitoring requirements?
**MWN-AI FAQ is based on asking OpenAI questions about Alzamend Neuro Inc. (NASDAQ: ALZN).
NASDAQ: ALZN
ALZN Trading
8.87% G/L:
$2.21 Last:
61,295 Volume:
$2.09 Open:
